... Rebif was the EVIDENCE trial. This was a head-to-head, randomized, open-label, evaluator-blinded comparison of Rebif 44 μg with Avonex 30 μg in patients with RRMS. This trial was required by the U.S. FDA in order for Rebif to enter the ...
This website uses cookies and collects data for optimal performance. Your continued use signifies agreement to our Privacy Policy.